Key Highlights

  • AbbVie (NYSE:ABBV) lifted its 2026 adjusted EPS guidance to USD 13.95 to USD 13.99, up from USD 13.76 to USD 13.96 previously. The new range is tighter than the prior one.
  • Q3 net Revenue reached USD 17.404 billion, up 10.3 percent, with adjusted EPS of USD 3.82 after a USD 0.11 acquired R&D charge. Immunology drugs drove most of the revenue growth.
  • Skyrizi sales came in at USD 5.776 billion and Rinvoq at USD 2.706 billion, each up more than 22 percent, while Humira slid 31.2 percent. That mix shows how growth leans on newer products.
  • A planned 5.2 percent Dividend increase to USD 1.82 per quarter is slated to start in February 2027, and shares rose about 3.2 percent in premarket. Both the dividend plan and the share gain may change.

What AbbVie Reported

AbbVie (NYSE:ABBV) reported Q3 results on October 30, 2026. Net revenue was USD 17.404 billion, up 10.3 percent, and adjusted EPS was USD 3.82 after an acquired R&D charge of USD 0.11. The company raised its 2026 adjusted EPS guidance to USD 13.95 to USD 13.99, from USD 13.76 to USD 13.96. Note that the new range lifts the low end more than the high end, which narrows the band. We verified these figures against a copy of the company release. We could not verify consensus EPS or revenue, so we do not claim a beat. Shares rose about 3.2 percent in premarket, a snapshot before the 9:30 a.m. ET open.

Growth Drivers and the Humira Drag

Skyrizi revenue hit USD 5.776 billion and Rinvoq USD 2.706 billion, each rising more than 22 percent. Combined, they generated about USD 8.5 billion, simple arithmetic on the two sales figures, which is close to half of net revenue. Humira, by contrast, dropped 31.2 percent, a pattern typical when a drug faces biosimilar competition and price cuts. Growth therefore depends on newer immunology drugs replacing that lost revenue. AbbVie (NYSE:ABBV) also announced FDA approvals and Phase 3 data, including lutikizumab in hidradenitis suppurativa and Epkinly, which widen the pipeline. Pipeline news matters because the older product keeps shrinking. Investors should watch whether combined growth holds as comparisons become harder.

Dividend, Risks and What to Watch

AbbVie (NYSE:ABBV) plans a 5.2 percent dividend increase to USD 1.82 per quarter from February 2027, a plan rather than a guarantee. Risks include continued Humira erosion, reliance on two drugs, acquired R&D charges that weigh on adjusted EPS and pricing pressure. Defensive sectors attracted buyers while technology sold off, with the consumer staples ETF up 2.08 percent and the health care ETF up 1.23 percent in premarket. Next catalysts are the open, analyst estimate changes, which we did not find, and further trial updates. The share price reaction can also reverse once the regular session begins.

Where Things Stand

AbbVie (NYSE:ABBV) lifted its 2026 adjusted EPS guidance to USD 13.95 to USD 13.99 because Skyrizi and Rinvoq each rose more than 22 percent, enough to outweigh a 31.2 percent decline in Humira. Without verified consensus figures, we do not call the quarter a beat. The 3.2 percent premarket gain is a snapshot. Upcoming catalysts are the open and pipeline news. This is not Investment advice. Investors should follow the company's future trial results and regulatory timelines for more detail.